Trevi Therapeutics (NASDAQ:TRVI) Given Buy Rating at B. Riley

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reiterated by stock analysts at B. Riley in a note issued to investors on Wednesday,Benzinga reports. They currently have a $20.00 price objective on the stock, up from their previous price objective of $11.00. B. Riley’s price objective indicates a potential upside of 199.99% from the company’s previous close.

A number of other equities analysts have also recently commented on the company. Needham & Company LLC reduced their price target on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $12.50 price target on shares of Trevi Therapeutics in a report on Wednesday. Oppenheimer lifted their price target on Trevi Therapeutics from $12.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. Raymond James upgraded Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price target for the stock from $9.00 to $29.00 in a report on Monday, March 10th. Finally, D. Boral Capital reiterated a “buy” rating and set a $21.00 price target on shares of Trevi Therapeutics in a report on Wednesday. Seven analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $17.56.

Trevi Therapeutics Stock Up 1.6 %

Trevi Therapeutics stock traded up $0.11 during mid-day trading on Wednesday, hitting $6.67. 528,663 shares of the company’s stock were exchanged, compared to its average volume of 2,002,299. The firm has a market capitalization of $512.47 million, a P/E ratio of -15.15 and a beta of 0.90. Trevi Therapeutics has a fifty-two week low of $2.30 and a fifty-two week high of $7.39. The company’s 50 day simple moving average is $4.44 and its 200-day simple moving average is $3.68.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.01. Research analysts expect that Trevi Therapeutics will post -0.49 EPS for the current year.

Insider Transactions at Trevi Therapeutics

In other news, insider Farrell Simon sold 81,313 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the transaction, the insider now directly owns 76,900 shares in the company, valued at approximately $519,075. This represents a 51.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 24.37% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. GSA Capital Partners LLP bought a new stake in shares of Trevi Therapeutics in the third quarter worth $409,000. Oppenheimer & Co. Inc. grew its stake in shares of Trevi Therapeutics by 34.7% in the third quarter. Oppenheimer & Co. Inc. now owns 81,947 shares of the company’s stock worth $274,000 after purchasing an additional 21,128 shares during the last quarter. MAI Capital Management grew its stake in shares of Trevi Therapeutics by 0.7% in the third quarter. MAI Capital Management now owns 1,327,285 shares of the company’s stock worth $4,433,000 after purchasing an additional 8,789 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Trevi Therapeutics in the third quarter worth $63,000. Finally, BNP Paribas Financial Markets grew its stake in shares of Trevi Therapeutics by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after purchasing an additional 6,764 shares during the last quarter. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.